Cantor Fitzgerald Reiterates Overweight on Oracle, $284 PT
Cantor Fitzgerald analyst Thomas Blakey reiterated an Overweight rating and $284 price target on Oracle (NYSE: ORCL).
“Oracle delivered a strong F1Q27, with total revenue growing 30% y/y to $19.3B, the first time F1Q revenue has grown sequentially off a F4Q print in company history, as cloud infrastructure revenue accelerated to +121% y/y.
Gross margin stepped down more than expected to ~61.0% on the ongoing data center ramp and mix shift toward infrastructure, but management continued to frame this as anticipated, pointing to maintaining-to-improving contractual margins and a 20% renewal/resale premium on capacity coming off contract as evidence of pricing power in a still supply-constrained environment.
Capex of $28.5B ran well ahead of street (Visible Alpha: $19.3B), though net cash outlay of $18.0B and the reaffirmed $90-95B FY27 capex / not-more-than-$70B net cash framework confirm Oracle continues to fund its build disproportionately with customer and supplier capital, further evidenced by the now-completed $20B ATM issuance.
RPO growth decelerated sharply to $26B q/q from $85B in F4Q26 on 850MW of delivered capacity, modestly below the ~1GW framing entering the print, while SaaS growth ticked up to 10% y/y cc but remained below street on continued NetSuite softness.
Multicloud database remained the standout growth vector at +353% y/y, and AI usage metrics across the applications suite continued to scale off a small base.
We view this print as broadly consistent with our thesis — durable infrastructure demand and underlying asset useful life and related strong pricing power against a backdrop of stable capital intensity — and continue to see attractive risk/reward in shares at current levels.
We reiterate our OW rating and $284 PT.”
The price target and rating on this page are the opinion of the issuing research firm and its analyst, not of Price Target. This page is published for informational purposes only and is not investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consider your own circumstances and consult a licensed financial adviser before making investment decisions.
This research note is reproduced verbatim from the issuing firm. Price Target never edits, paraphrases or alters analysts’ words — we only republish them in one place.





